1. Home
  2. BPT vs EQ Comparison

BPT vs EQ Comparison

Compare BPT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPT
  • EQ
  • Stock Information
  • Founded
  • BPT 1989
  • EQ 2017
  • Country
  • BPT United States
  • EQ United States
  • Employees
  • BPT N/A
  • EQ N/A
  • Industry
  • BPT Integrated oil Companies
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • BPT Energy
  • EQ Health Care
  • Exchange
  • BPT Nasdaq
  • EQ Nasdaq
  • Market Cap
  • BPT 22.3M
  • EQ 24.8M
  • IPO Year
  • BPT N/A
  • EQ 2018
  • Fundamental
  • Price
  • BPT $0.46
  • EQ $0.64
  • Analyst Decision
  • BPT
  • EQ Buy
  • Analyst Count
  • BPT 0
  • EQ 2
  • Target Price
  • BPT N/A
  • EQ $5.00
  • AVG Volume (30 Days)
  • BPT 441.1K
  • EQ 141.5K
  • Earning Date
  • BPT 03-13-2025
  • EQ 11-13-2024
  • Dividend Yield
  • BPT N/A
  • EQ N/A
  • EPS Growth
  • BPT N/A
  • EQ N/A
  • EPS
  • BPT N/A
  • EQ N/A
  • Revenue
  • BPT $257,000.00
  • EQ $45,914,000.00
  • Revenue This Year
  • BPT N/A
  • EQ $4.76
  • Revenue Next Year
  • BPT N/A
  • EQ N/A
  • P/E Ratio
  • BPT N/A
  • EQ N/A
  • Revenue Growth
  • BPT N/A
  • EQ 7.70
  • 52 Week Low
  • BPT $0.40
  • EQ $0.56
  • 52 Week High
  • BPT $3.20
  • EQ $3.25
  • Technical
  • Relative Strength Index (RSI)
  • BPT 32.36
  • EQ 39.10
  • Support Level
  • BPT $0.40
  • EQ $0.64
  • Resistance Level
  • BPT $0.57
  • EQ $0.73
  • Average True Range (ATR)
  • BPT 0.07
  • EQ 0.08
  • MACD
  • BPT -0.00
  • EQ -0.00
  • Stochastic Oscillator
  • BPT 13.58
  • EQ 10.12

About BPT BP Prudhoe Bay Royalty Trust

BP Prudhoe Bay Royalty Trust is a grantor trust operating in the US. The property of the Trust consists of an overriding royalty interest. The Royalty Interest entitles the Trust to receive the royalty from the production of crude oil and condensate from the working interest of BP Exploration (Alaska) Inc. in the Prudhoe Bay oil field located on the North Slope of Alaska.

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Share on Social Networks: